"Ethical Concerns Surrounding Ozempic and Other Injectable Weight Loss Drugs"

In the podcast "Chasing Life," CNN's Dr. Sanjay Gupta discusses the booming business of weight loss drugs, such as Ozempic, Wegovy, Mounjaro, and Zepbound, with colleague Meg Tirrell. The demand for these medications has surged, with U.S. healthcare providers writing over 9 million prescriptions in the last three months of 2022 alone, despite their high cost of about $1,000 a month. The rise of these drugs, particularly GLP-1 drugs, has surprised many due to previous failures in the weight loss medication space. The industry is projected to reach $100 billion in annual revenue by 2030, with companies like Novo Nordisk and Eli Lilly dominating the market and struggling to keep up with demand.